Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record.

Abstract LB422: Selective targeting of CDK2 using molecular glue degraders for the treatment of HR-positive/HER2-negative breast cancer

Abstract

Cyclin dependent kinases 4 and 6 (CDK4 and CDK6) and cyclin dependent kinase 2 (CDK2) act in a coordinated fashion to phosphorylate and repress RB protein, effectively driving cell proliferation via E2F activation. Currently, CDK4/6 inhibitors in combination with endocrine therapy are considered the standard of care for the treatment of hormone-receptor (HR)-positive/HER2-negative breast cancer, but unfortunately most patients with metastatic disease ultimately progress. High CCNE1 expression is considered one of the underlying mechanisms of resistance to CDK4/6-inhibition, and other adaptations to chronic CDK4/6-inhibition that increase reliance on the CDK2 pathway to sustain RB-E2F signaling are also thought to reduce CDK4/6 inhibitor effectiveness. Based on this, we reason that, targeting CDK2 in conjunction with CDK4/6 inhibition can provide more sustained and durable responses in this difficult-to-treat patient population. To identify molecular glue degraders (MGDs) that selectively target CDK2, we used our MGD discovery engine QuEENTM. Through this platform that encompasses biochemical and cellular assays as well as in silico modelling, we identified and further optimized molecules that induce CRBN engagement to drive selective CDK2 degradation. Unlike CDK2 inhibitors, our CDK2 MGDs spare other proteins such as closely related CDKs and, attesting to their superior selectivity, inhibit cell proliferation in an RB-dependent manner. Furthermore, these MGDs induce robust downstream pathway suppression, as evidenced by downmodulation of RB phosphorylation and E2F-driven gene expression. When dosed orally in in vivo models of HR-positive/HER2-negative breast cancer, these compounds drive deep tumor regression in combination with CDK4/6 inhibitor or triple combination with endocrine therapy (fulvestrant), resulting in enhanced downstream pathway suppression compared to CDK4/6 inhibitor alone. Owing to their superior selectivity, we expect that a CDK2 MGDs will avoid dose-limiting toxicities associated with less selective CDK2 inhibitors. Hence, CDK2 MGDs provide novel means to target an inadequately drugged target, offering a unique angle for populations in desperate need of treatment options. Citation Format: Sofia Gkountela, William Tahaney, Vasiliki Vafeiadou, Christelle Bianda, Liam Cheeseman, Ambika Singh, Anna Diesslin, Martin Schillo, Sophia Nguyen, Luca Moccia, Christopher King, Yimao Liu, Chao Quan, Bradley DeMarco, Laura Schwander, Vaik Strande, Jessica Alers, Rajiv Narayan, Dave Peck, Sarah Pessa, Samuel Gilberto, John Castle, Filip Janku, Sharon Townson, Markus Warmuth, Magnus Walter, Beatrice Ranieri, Ralph Tiedt, Nina Ilic Widlund. Selective targeting of CDK2 using molecular glue degraders for the treatment of HR-positive/HER2-negative breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_2):Abstract nr LB422.

Overview

Integrity signals

Registry

Crossref · 10.1158/1538-7445.am2025-lb422

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Still being checked.

Cited by

See all 7

Metadata

Authors
Gkountela, S., Tahaney, W., Vafeiadou, V., Bianda, C., Cheeseman, L., Singh, A., Diesslin, A., Schillo, M., Nguyen, S., Moccia, L., King, C., Liu, Y., Quan, C., DeMarco, B., Schwander, L., Strande, V., Alers, J., Narayan, R., Peck, D., Pessa, S., Gilberto, S., Castle, J., Janku, F., Townson, S., Warmuth, M., Walter, M., Ranieri, B., Tiedt, R., & Widlund, N. I.
Affiliations
  • 1Monte Rosa Therapeutics AG, Basel, Switzerland;
  • Massachusetts Institute for a New Commonwealth (US)
  • 2Monte Rosa Therapeutics, Inc., Boston, MA.
Venue
Cancer Research
Published
2025-04-25
Volume
85
Issue
8_Supplement_2
Pages
LB422-LB422
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W4409821144
Cited by
7
References
0
Citations by year
2026: 7
Type
conference abstract
Language
en
Open access
closed
Locations
Cancer Research (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
  • Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Keywords
CDK2, molecular glues, hormone receptor-positive HER2-negative breast cancer, CDK4/6 inhibitors, cereblon, cyclin E1, drug resistance, fulvestrant, endocrine therapy, selective protein degradation, oral anticancer drugs, metastatic breast cancer, cell proliferation inhibition

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Abstract LB422: Selective targeting of CDK2 using molecular glue degraders for the treatment of HR-positive/HER2-negative breast cancer. https://app.cochat.ai/papers/10.1158/1538-7445.am2025-lb422
The paper
Gkountela, S., Tahaney, W., Vafeiadou, V., Bianda, C., Cheeseman, L., Singh, A., Diesslin, A., Schillo, M., Nguyen, S., Moccia, L., King, C., Liu, Y., Quan, C., DeMarco, B., Schwander, L., Strande, V., Alers, J., Narayan, R., Peck, D., . . . Widlund, N. I. (2025). Abstract LB422: Selective targeting of CDK2 using molecular glue degraders for the treatment of HR-positive/HER2-negative breast cancer. Cancer Research. https://doi.org/10.1158/1538-7445.am2025-lb422

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.